How to Take Estrogen and Medroxyprogesterone for HRT: Dosing and Timing
For women with an intact uterus requiring hormone replacement therapy, administer transdermal 17β-estradiol continuously (50-100 μg daily via patches changed twice weekly) combined with oral medroxyprogesterone acetate 10 mg daily for 12-14 days every 28 days, or alternatively use continuous combined therapy with 2.5 mg medroxyprogesterone acetate daily. 1
Estrogen Administration
Route Selection
Transdermal estrogen is the preferred first-line route due to avoidance of hepatic first-pass metabolism, which reduces cardiovascular and thromboembolic risks—particularly important for women with hypertension, hypertriglyceridemia, or increased thrombosis risk 1. The 2021 guidelines specifically emphasize transdermal 17β-estradiol as first choice for women at higher cardiovascular risk 2.
Transdermal Dosing
- Patches releasing 50-100 μg of 17β-estradiol per 24 hours
- Change twice weekly or weekly depending on brand specifications 2
- Administer continuously without interruption 2
Oral Alternative (Second Choice)
If transdermal route is contraindicated or refused:
- 1-2 mg oral 17β-estradiol daily 2
- Oral route has higher interindividual variability and hepatic effects 1
Medroxyprogesterone Acetate (MPA) Administration
All women with an intact uterus must receive progestogen for endometrial protection to prevent endometrial hyperplasia and cancer 1, 3.
Sequential (Cyclic) Regimen - Preferred for Younger Women
10 mg MPA orally for 12-14 days every 28 days 1, 2, 1
- Induces predictable withdrawal bleeding
- Provides adequate endometrial protection 1, 4
- Example: Days 1-28 continuous estrogen, add MPA days 15-28 (or 15-26) 2
Key advantage: Recent evidence suggests cyclical administration may have lower cardiovascular and thromboembolism risk compared to continuous regimens 2
Continuous Combined Regimen - For Avoiding Withdrawal Bleeding
2.5 mg MPA orally daily (taken continuously with estrogen) 1
- Achieves amenorrhea in 76-80% of women by 6 months 4, 5
- By 24 months, 90-94% are amenorrheic 4
- Approximately 42% experience breakthrough bleeding in first 3 months, decreasing over time 4
Alternative continuous dose: 5 mg MPA daily also provides endometrial protection 1, 6
Practical Regimen Examples
Option 1: Sequential Combined (Induces Monthly Bleeding)
- Transdermal 17β-estradiol 50 μg patch continuously (change twice weekly)
- Plus oral MPA 10 mg daily for days 15-28 of each 28-day cycle 2
Option 2: Continuous Combined (Avoids Bleeding)
- Transdermal 17β-estradiol 50 μg patch continuously (change twice weekly)
- Plus oral MPA 2.5 mg daily without interruption 2, 5
Option 3: Combined Patches (Best Compliance)
If available, use combined estradiol-progestin patches for improved adherence 2:
- Sequential: 17β-estradiol alone for 2 weeks, then combined 17β-estradiol + levonorgestrel for 2 weeks
- Continuous: Combined patches changed continuously without interruption
Important Clinical Considerations
Timing of Initiation
- Optimal window: Within 10 years of menopause or before age 60 7, 8
- Starting after age 65 increases cardiovascular and dementia risks 8, 9
Duration of Therapy
- Continue until average age of natural menopause (45-55 years) for premature ovarian insufficiency 2
- For standard menopause management: use lowest effective dose for symptom control 3, 10
- The 2025 FDA removal of the "shortest duration" mandate allows individualized duration based on benefits and risks 7
Monitoring
- Do NOT use FSH levels to monitor adequacy—they remain elevated despite adequate tissue effects 1
- Monitor bone density with DEXA scans 1
- Assess cardiovascular risk factors and lipid profiles 1
Common Pitfalls to Avoid
Never use unopposed estrogen in women with intact uterus—this dramatically increases endometrial cancer risk 3, 10
Insufficient progestogen duration: Must give progestogen for minimum 10-14 days monthly in sequential regimens 1, 3—shorter durations provide inadequate endometrial protection
Starting too late: Initiating HRT after age 65 or >20 years post-menopause increases cardiovascular risks without the protective benefits seen with earlier initiation 8, 9
Expecting immediate amenorrhea with continuous regimens: Counsel patients that 40-50% will have breakthrough bleeding in first 3-6 months, which typically resolves 4, 5
Women Without a Uterus (Post-Hysterectomy)
Use estrogen-only therapy without progestogen 10, 9:
- Transdermal 17β-estradiol 50-100 μg daily continuously
- Or oral conjugated equine estrogen 0.625 mg daily
- No need for progestogen adds, which may increase breast cancer risk 9